Streetbeat News

Stock Prices

NIO

TSLA

NIO Inc's shares are trading lower due to selling pressure after Tesla Inc lowered its prices in China and weak economic data from China. Tesla's price cut is forcing competing EV makers to stay competitive on cost. China's economic weakness is evident in slower growth in retail sales, industrial output, and broader investments. NIO's Hardware vice president announced that some of the company's key self-developed chips will be mass produced in the next one to two years.

Portfolio Pulse from Adam Eckert

August 15, 2023 | 1:08 pm

MGOL

MGO Global's shares are trading lower following the release of the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:07 pm

TLSA

Tiziana Life Sciences announced that the FDA has cleared its Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:06 pm

AREN

ASTS

CSSE

GETY

GRND

MOXC

TGL

TME

TOON

WIMI

Several communication services stocks experienced significant movement in Tuesday's pre-market session. Notable gainers included Grindr, Arena Group Holdings, Moxian, Treasure Global, WiMi Hologram Cloud, and AST SpaceMobile. On the other hand, Chicken Soup for the Soul, Sea, Getty Images Holdings, Kanzhun, Tencent Music Enter Gr, and Kartoon Studios saw their stocks decline. Q2 earnings reports were a common factor in these movements.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 1:06 pm

BFI

CENN

FTEL

FXLV

GNS

GROV

LXEH

MGOL

TLYS

TRNR

XWEL

Several consumer discretionary stocks experienced significant movement in Tuesday's pre-market session. Interactive Strength (TRNR), Grove Collaborative Hldgs (GROV), LL Flooring Holdings (LL), Cenntro Electric Gr (CENN), Lixiang Education Hldg (LXEH), and BurgerFi International (BFI) saw gains, while F45 Training Holdings (FXLV), MGO Global (MGOL), Fitell (FTEL), XWELL (XWEL), Tilly's (TLYS), and Genius Gr (GNS) experienced losses.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 1:06 pm

DCTH

DSGN

GLTO

TLSA

Several healthcare stocks experienced significant movement in Tuesday's pre-market session. Notable gainers included Delcath Systems (DCTH), Tiziana Life Sciences (TLSA), G Medical Innovations (GMVD), SCYNEXIS (SCYX), Taysha Gene Therapies (TSHA), and Evoke Pharma (EVOK). On the other hand, Galecto (GLTO), Design Therapeutics (DSGN), Alaunos Therapeutics (TCRT), OptimizeRx (OPRX), TFF Pharmaceuticals (TFFP), and PHAXIAM Therapeutics (PHXM) saw declines.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 1:06 pm

EFSH

FRGT

JOB

RCRT

In Tuesday's pre-market session, several industrial stocks saw significant movement. Gainers included Recruiter.Com Group (RCRT), GEE Group (JOB), Pioneer Power Solutions (PPSI), VirTra (VTSI), Agrify (AGFY), and Heliogen (HLGN). Losers included 1847 Holdings (EFSH), Freight Technologies (FRGT), Intuitive Machines (LUNR), VCI Global (VCIG), WANG & LEE Group (WLGS), and Applied UV (AUVI). Most of these movements were in response to Q2 earnings releases.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 1:06 pm

ACLX

The FDA has lifted the partial clinical hold on Arcellx Inc's iMMagine-1 Phase 2 Clinical Program. The decision comes after modifications were made to the trial protocol to better manage the risk of adverse events. Arcellx has retrained clinical sites and expanded treatment options for therapies that patients can receive. Preliminary data from the study is expected in the second half of 2024. Arcellx's shares are down 0.09% at $33.66 premarket.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 1:05 pm

GNL

RTL

Orange Capital plans to vote against the merger of Global Net Lease (GNL) and Retail REIT (RTL), citing concerns over dilution of GNL's high-quality portfolio, inferior business quality of RTL, substantial dilutive stock issuance, high internalization costs, and limited strategic alternatives post-merger. Orange Capital suggests alternatives such as a stand-alone internalization of GNL, a potential sale of GNL to a third party, or continuation of the current status quo.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 1:05 pm

DSGN

Design Therapeutics Inc (NASDAQ:DSGN) reported initial results from its Phase 1 clinical trial of DT-216 in patients with Friedrich ataxia (FA). The results showed that DT-216 was generally well-tolerated and achieved a significant increase in frataxin (FXN) mRNA levels. However, injection site reactions were observed, leading the company to plan a reformulation of the drug. A new Phase 1 study is planned for the second half of 2024. DSGN shares are down 45.7% in premarket trading.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 1:05 pm